News

Baltic biotech attracts investors
Enlarge image

BusinessLithuaniaLatviaEstoniaDenmarkGermanySweden

Baltic biotech attracts investors

17.09.2012 - The very first Life Science Baltics 2012 attracted twice as many visitors than anticipated. Investors are lured by EU funds, low cost and qualified staff.

The very first Life Science Baltics conference almost 800 life science professionals visiting Vilnius. „That’s almost twice than we expected“, Jelena Suchodumceva, Senior Project Manager at Enterprise Lithuania, told EuroBiotechNews at the conference. According to the organisers from the governmental agency, more than 80% of the attendants came from non-Baltic states such as Israel, Canada, the US or EU member states. A trade fair showcasing the offerings of more than 40 companies and over 100 pre-scheduled B2B meetings reflected the huge interest to invest in the Baltic scene.

At the conference, ThermoFisher Scientific stated it will inaugurate a €16m research and production facility next week on the grounds of former Lithuanian Fermantas AB. Furthermore, Biotechpharma UAB received an €11m cash injection from EU structural funds. The money helped the Lithuanian CMO to build a state-of-the-art biopharmaceutical facility, which will become fully operational next year at Santara Valley, a brand-new life sciences-IT incubator in the country’s capital. The cluster is one of 5 high-tech valleys supported by the Lithuanian government with investments of €400m.

Prof. Dr. Vladas Bumelis, Chairman of Biotechpharma and Lithuanian biotech mastermind, said at the conference that investors are attracted by the strong knowledge base, low cost of goods and the governmental commitment to support the life sciences sector. To become a big fish within the life science scene, however, it would be essential for the many but small firms in the Baltic region to swim in formation. According to Enterprise Lithuania, the country’s life sciences industry has been skyrocketing over the last two decades with an annual growth rate of 22%, and over 80% of the production being exported. Last year, exports from the life sciences sector amounted to €276.2m. Its main export markets were Sweden (21.1% of the total); Germany (10.9%); Italy (8.1%); UK (6.%); Denmark (6.7%); Russia (4.7%); Norway (4.6%); Poland (4.3%); France (4%); and Latvia (2.7%).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/baltic-biotech-attracts-investors.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON10.43 EUR7.08%
  • EVOTEC3.27 EUR4.47%
  • MORPHOSYS78.71 EUR1.88%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • 4SC0.89 EUR-5.32%
  • CYTOS0.28 CHF-3.45%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.14 EUR45.6%
  • FORMYCON10.43 EUR32.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.54 EUR-12.4%
  • CO.DON2.50 EUR-9.1%

TOP

  • SANTHERA92.25 CHF2505.9%
  • CO.DON2.50 EUR140.4%
  • BB BIOTECH183.00 EUR63.5%

FLOP

  • CYTOS0.28 CHF-91.6%
  • 4SC0.89 EUR-48.6%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014